Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Oncolytics Biotech announced promising initial preclinical data showing enhanced anti-tumor activity when their immunotherapy pelareorep is combined with RAS pathway inhibitors in solid tumor models. These findings support further studies in pancreatic and colorectal cancers that harbor RAS mutations, aiming to improve immune activation and treatme…